Johnson & Johnson: Alzheimer’s Disease Pipeline Could Dominate


  • Johnson & Johnson selected a vaccine to take to Phase 3.
  • Another rival amyloid beta antibody could appear on the market next year.
  • The antibodies are limited by safety restrictions which don’t involve Johnson & Johnson’s candidates.

World Alzheimer"s day. Paper silhouette of human head with red tangled threads on blue background. Flat lay. Concept of mental health and dementia

Ildar Abulkhanov/iStock via Getty Images

November was a fateful month in the Alzheimer’s disease (or AD) field, as gantenerumab from Roche (OTCQX:RHHBY) bowed out with twin readout failures on the 14th, slowing cognitive decline relative to placebo by

ACI-35.030 is highly immunogenic

AC Immune Investor Presentation

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Leave a Reply

Your email address will not be published. Required fields are marked *